Selective DNA methylation of BDNF promoter in bipolar disorder: Differences among patients with BDI and BDII

Neuropsychopharmacology

Volumn 37, Issue 7, 2012, Pages 1647-1655

  D'Addario, Claudio ^a   Dell'Osso, Bernardo ^b   Palazzo, Maria Carlotta ^b   Benatti, Beatrice ^b   Lietti, Licia ^b   Cattaneo, Elisabetta ^b   Galimberti, Daniela ^b   Fenoglio, Chiara ^b   Cortini, Francesca ^b   Scarpini, Elio ^b   Arosio, Beatrice ^b   Di Francesco, Andrea ^a   Di Benedetto, Manuela ^c   Romualdi, Patrizia ^c   Candeletti, Sanzio ^c   Mari, Daniela ^b   Bergamaschini, Luigi ^b   Bresolin, Nereo ^b   MacCarrone, Mauro ^a,d   Altamura, A Carlo ^b  

^a UNIVERSITY OF TERAMO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

bipolar disorder (BD); brain derived neurotrophic factor (BDNF); DNA methylation; Gene expression; mood stabilizers and antidepressants; peripheral blood mononuclear cells (PBMCs)

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOMIPRAMINE; DNA; DULOXETINE; ESCITALOPRAM; GABAPENTIN; LITHIUM; MOOD STABILIZER; OLANZAPINE; PREGABALIN; QUETIAPINE; SERTRALINE; VALPROIC ACID; VENLAFAXINE;

ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG MECHANISM; EPIGENETICS; FEMALE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC;

EID: 84861190781     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.10     Document Type: Article

References (73)

1. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F et al (2006). Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15: 3132-3145. (Pubitemid 44607800)
2. Abdolmaleky HM, Thiagalingam S, Wilcox M (2005). Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 5: 149-160. (Pubitemid 40994274)
3. Arosio B, Viazzoli C, Mastronardi L, Bilotta C, Vergani C, Bergamaschini L (2010). Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment. J Alzheimers Dis 20: 991-996.
4. Brunoni AR, Lopes M, Fregni F (2008). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11: 1169-1180.
5. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S (2007). Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 91: 1-5.
6. Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O et al (2007). A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18: 1529-1538. (Pubitemid 47365487)
7. Castrén E, Rantamäki T (2010). The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 70: 289-297.
8. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50: 260-265. (Pubitemid 32778442)
9. Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL et al (2009). Decreased levels of serum brain-derived neurotrophic factor in drug-na?̈ve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 07: 375-380.
10. Chomczynski P, Sacchi N (2006). The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 1: 581-585.
11. Chuang D-M (2004). Lithium protection from glutamate excitotoxicity: therapeutic implications. ClinNeurosci Res 4: 243-252. (Pubitemid 40197847)
12. Coyle JT, Duman RS (2003). Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38: 157-160. (Pubitemid 36555643)
13. Craddock N, Jones I (2001). Molecular genetics of bipolar disorder. Br J Psychiatry 178: 128-133. (Pubitemid 32530340)
14. Das Das S, Kubota T, Song M, Daniel R, Berry-Kravis EM, Prior TW et al (1997-1998). Methylation analysis of the fragile X syndrome by PCR. Genet Test 1: 151-155.
15. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A (2008). Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci USA 105: 13614-13619.
16. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003). Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60: 804-815. (Pubitemid 36960912)
17. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L et al (2003). The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23: 7311-7316. (Pubitemid 36999520)
18. Feng J, Fouse S, Fan G (2007). Epigenetic regulation of neural gene expression and neuronal function. Pediatr Res 2007 61(5 Pt 2): 58R-63R. . (Pubitemid 46653070)
19. First MB, Gibbon M, Spitzer RL (1997). Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). American Psychiatric Press: Washington DC. .
20. First MB, Spitzer RL, Gibbon L, Williams JBV (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York State Psychiatric Institute, Biometric Research: New York. .
21. First MB, Spitzer RL, Gibbon L, Williams JBV (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York State Psychiatric Institute, Biometric Research: New York. .
22. Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki S, Ozaki N et al (2011). DNA methylation profiles of the brainderived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One 6: e23881.
23. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T (2000). DNA methyl transferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24: 88-91. (Pubitemid 30041428)
24. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T (2003). The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278: 4035-4040. (Pubitemid 36801137)
25. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001). Chronic lithium treatment increases the expression of brain derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158: 100-106.
26. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S et al (2006). Phase 1/2 study of the combination of 5-aza-20-deoxycytidine with valproic acid in patients with leukemia. Blood 108: 3271-3279.
27. Gavin DP, Sharma RP (2010). Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev 34: 882-888.
28. Geller B, Badner JA, Tillman R (2004). Linkage disequilibrium of the brain derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry 161: 1698-1700. (Pubitemid 39201469)
29. Gershon ES (2000). Bipolar illness and schizophrenia as oligogenic diseases: implications for the future. Biol Psychiatry 47: 240-244. (Pubitemid 30077400)
30. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 5: 421-433. (Pubitemid 38072244)
31. Grande I, Fries GR, Kunz M, Kapczinski F (2010). The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 7: 243-250.
32. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A et al (2005). Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 102: 9341-9346. (Pubitemid 40923565)
33. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ et al (2010). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 11: 81-109.
34. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
35. Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P et al (2004). Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 24: 6590-6599. (Pubitemid 38971708)
36. Hashimoto K, Shimizu E, Iyo M (2004). Critical role of brainderived neurotrophic factor in mood disorders. Brain Res Rev 45: 104-114. (Pubitemid 38625738)
37. Henikoff S, Matzke MA (1997). Exploring and explaining epigenetic effects. Trends Genet 13: 293-295.
38. Iga J, Ueno S, Yamauchi K, Numata S, Motoki I, Tayoshi S et al (2006). Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett 400: 203-207.
39. Jirtle RL, Skinner MK (2007). Environmental epigenomics and disease susceptibility. Nat Rev Genet 8: 253-262. (Pubitemid 46439287)
40. Kapczinski F, Frey BN, Kauer-Sant'Anna M, Grassi-Oliveira R (2008). Brain derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 8: 1101-1113. (Pubitemid 351962077)
41. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005). Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136: 29-37. (Pubitemid 40704606)
42. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT et al (2009). Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs late-stage bipolar disorder. Int J Neuropsychopharmacol 12: 447-458.
43. Klose RJ, Bird RP (2006). Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31: 89-97. (Pubitemid 43221841)
44. Levenson JM, Roth TL, Lubin FD, Miller CA, Huang IC, Desai P et al (2006). Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem 281: 15763-15773. (Pubitemid 43848466)
45. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
46. Lu X, Freund JN, Muller M, Ravey J, Nicolas JP, Gueant JL et al (2008). Differential regulation of CDX1 and CDX2 gene expression by deficiency in methyl group donors. Biochimie 90: 697-704.
47. Lyon E (2001). Mutation detection using fluorescent hybridization probes and melting curve analysis. Expert Rev Mol Diagn 1: 92-101. (Pubitemid 34654451)
48. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y et al (2003). DNA methylation-related chromatin remodeling in activitydependent BDNF gene regulation. Science 302: 890-893. (Pubitemid 37339633)
49. Maxwell ME (1992). The Family Interview for Genetic Studies Manual. National Institute of Mental Health, Intramural Research Program, Clinical Neurogenetics Branch: Washington. .
50. Mill J, Petronis A (2009). The relevance of epigenetics to major psychosis. Epigenomics (Part IV): 411-434.
51. Mill J, Tanq T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L et al (2008). Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 82: 696-711. (Pubitemid 351726115)
52. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389. (Pubitemid 9136500)
53. Nakata K, Ujike H, Sakai A (2003). Association study of the brain derived neurotrophic factor (BDNF) gene with bipolar disorder. Neurosci Lett 337: 17-20. (Pubitemid 36078301)
54. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN et al (1998). Transcriptional repression by the methyl-CpGbinding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389. (Pubitemid 28269714)
55. Nelson W, Luo M, Ma J, Estep M, Estill J, He R et al (2008). Methylation-sensitive linking libraries enhance gene-enriched sequencing of complex genomes and map DNA methylation domains. BMC Genomics 9: 621.
56. Neves-Perreira M, Mundo E, Muglia P (2002). The brain derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family based association study. Am J Hum Genet 71: 651-655. (Pubitemid 34970137)
57. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539-7547.
58. Pandey GN, Rizavi HS, Dwivedi Y, Pavuluri MN (2008). Brainderived neurotrophic factor gene expression in pediatric bipolar disorder: effects of treatment and clinical response. J Am Acad Child Adolesc Psychiatry 47: 1077-1085.
59. Petronis A (2003). Epigenetics and Bipolar Disorder: new opportunities and changes. Am J Med Genet C Semin Med Genet 123: 65-75. (Pubitemid 37356434)
60. Pidsley R, Mill J (2011). Epigenetic studies of psychosis: current findings, methodological approaches and implications for postmortem research. Biol Psychiatry 69: 146-156.
61. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D et al (2008). Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 10: 1-5.
62. Roceri M, Hendriks W, Racagni G, Ellenbroek BA, Riva MA (2002). Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. Mol Psychiatry 7: 609-616.
63. Russo-Neustadt A, Beard RC, Cotman CW (1999). Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21: 679-682. (Pubitemid 29486636)
64. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L et al (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356: 1711-1722. (Pubitemid 46658703)
65. Sen S, Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64: 527-532.
66. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251-3261. (Pubitemid 35379212)
67. Sklar P, Gabriel SB, McInnis MG (2002). Family based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol Psychiatry 7: 579-593.
68. Smith MA, Makino S, Kvetnanskỳ R, Post RM (1995). Effects of stress on neurotrophic factor expression in the rat brain. Ann NY Acad Sci 771: 234-239. (Pubitemid 26077410)
69. Timmuskb T (1993). Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 10: 475-489.
70. Tost J (2010). DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol Biotechnol 44: 71-81.
71. Tsankova N, Renthal W, Kumar A, Nestler EJ (2007). Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8: 355-367. (Pubitemid 46652469)
72. Yasuda M, Fukuchi M, Tabuchi A, Kawahara M, Tsuneki H, Azuma Y et al (2007). Robust stimulation of TrkB induces delayed increases in BDNF and Arc mRNA expressions in cultured rat cortical neurons via distinct mechanisms. J Neurochem 103: 626-636. (Pubitemid 47498045)
73. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-435. (Pubitemid 9006756)